211 
Market Cap
Stock Chart
Starpharma - 30 day Poll
Recent BLOGS About Starpharma Add New
Latest Company News
|
Starpharma Holdings Limited : Starpharma's dendrimers improve efficacy of ...
4-traders (press release) - Feb 1, 2012 Melbourne, Australia; 1 February 2012: Starpharma Holdings (ASX: SPL, OTCQX: SPHRY) today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma's dendrimer technology to the leading chemotherapy drug ...
|
|
Market Wrap: Aus shares up 0.85%
Finance News Network (press release) - Jan 11, 2012 The S&P/ASX 200 Index gained 35 points to finish at 4188. On the futures market, the SPI is 38 points higher. The Bureau of Statistics says the total number of Australian job vacancies for November fell 0.8 per cent to 182200.
|
|
Starpharma gets binding agreement for VivaGel
Finance News Network (press release) (subscription) - Jan 11, 2012 Starpharma Holdings Limited (ASX:SPL) (OCTQX:SPHRY) has received binding agreement from the Food and Drug Administration on the design of its phase three clinical studies of VivaGel, its lead product.
|
|
Starpharma Holdings Limited Announces Advancement Of Drug Delivery Collaboration
Reuters Key Development - Dec 18, 2011 |
|
Starpharma Holdings Limited Completes AUD 32 Million Placement
Reuters Key Development - Nov 15, 2011 |
|
Starpharma Holdings Limited Not To Pay FY 2011 Final Dividend
Reuters Key Development - Aug 29, 2011 |
Website
Videos related to Starpharma
Company Profile
Cash Balance & Finances
Starpharma reported negative cash flow of approx. $1.8m for quarter ended 31 Dec 2011.
Cash in hand at the end of the quarter was approx. $49m.
ASX and OTCQX listed
Commercial relationships include: Dade Behring (Siemens), SSL (Durex condoms), Elanco (Eli Lilly), EMD Merck, Sigma Aldrich, Stiefel Inc., Qiagen
Largest shareholders include: Dow Chemical Co., Acorn, Platinum LLC; ~22% US shareholding
Starpharma Holdings Limited is an Australia-based company engaged in the development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. Activities within the Company are directed towards the development of nano-scale materials, with a particular focus on the development of its topical vaginal microbicide, VivaGel, for the prevention of genital herpes and human immunodeficiency virus (HIV), and the application of dendrimers to drug delivery and other life science applications.
It is also engaged in exploring dendrimer opportunities in materials science with applications in areas, such as adhesives, lubricants and water remediation. The activities are managed by the Company’s wholly owned subsidiaries Starpharma Pty Ltd. in Melbourne and Australia, and Dendritic Nanotechnologies (DNT), Inc. in Michigan, United States.
The company predicts the world’s first herpes-killing vaginal gel may go on sale by 2012 and they plan to start patient studies on its effectiveness for genital herpes in 2010-11. Chief Executive Officer Jackie Fairley said in an interview in Singapore, declining to identify the partners. The Melbourne-based company licensed its VivaGel- coated condoms in 2008 to SSL International Plc, maker of the world’s best-selling Durex brand.